Phase II Study - Trial of a Phototherapy Light Device to Improve Sleep Health (PHOTONS)
1. november 2021 oppdatert av: MICHAEL A GRANDNER, University of Arizona
There are few devices currently on the market claiming to improve sleep.
This study will investigate the efficacy of phototherapy on improving sleep, in the form of a wearable neck device used at night.
Studieoversikt
Detaljert beskrivelse
This study will investigate the efficacy of phototherapy on improving sleep, in the form of a wearable neck device used at night.
Phototherapy has been shown to improve chronic pain, cerebral blood flow, neurological function, and capillary growth in skeletal muscle.
A device worn at night may improve sleep onset, total sleep time, or modify sleep architecture.
Improved cardiovascular function may facilitate a decrease in core body temperature needed for sleep onset.
Relaxation from direct heat may help to decrease cortisol levels, thus reducing the number of night-time arousals.
It may also decrease circulating levels of norepinephrine (NE), one of the main neurotransmitters involved in arousal.
The aim of this study is to evaluate if the device worn leads to greater next-day wellbeing and cognitive function as a result of increased slow-wave activity.
Studietype
Intervensjonell
Registrering (Forventet)
30
Fase
- Fase 2
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85719
- Rekruttering
- Department of Psychiatry, University of Arizona
-
Ta kontakt med:
- Michael A Grandner, PhD
- Telefonnummer: 520-626-6246
- E-post: grandner@email.arizona.edu
-
Ta kontakt med:
- Chloe CA Wills
- Telefonnummer: 520 626 1737
- E-post: chloecawills@psychiatry.arizona.edu
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
30 år til 60 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Between the ages of 18 and 60 years old
- Able to read and write fluently in English
- Access to a mobile device for video calls, online questionnaires, syncing devices, and communication with study staff
- Access to a residential mailing address for shipping study materials
- Exhibit a score of >8 on the Insomnia Severity Index
- Self-report that they have a problem with their sleep that they wish to improve
Exclusion Criteria:
- Have a moderate to severe current sleep disorder
- Have a current psychiatric disorder
- Are taking medication that would interfere with sleep, including beta blockers, antidepressants, antianxiety medications, hypnotics, or stimulants
- Have a medical condition that would interfere with their ability to complete all study procedures or would render measurements invalid (e.g., some autoimmune conditions, cardiac conditions, endocrine conditions, or chronic pain conditions)
- Exhibit a regular sleep schedule, where bed and wake times are kept within a 2-hour window 7 days per week
- Exhibit a regular sleep schedule during the night, beginning no earlier than 9pm and ending no later than 10am
- Have not engaged in shift work for the past month, and will refrain from shift work during the study
- Are unable to restrict alcohol consumption to no more than 2 drinks within 4 hours of sleep
- Are unable to restrict caffeine use to no coffee or caffeinated beverages after 12pm during the study
- Regularly smoke or use other tobacco products
- Regularly use cannabis-derived medicinal products
- Are pregnant
- Are a full-time caregiver to an individual that requires attending during the evening and night
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Active
An active phototherapy device
|
The active phototherapy device will emit light
|
|
Sham-komparator: Sham (Placebo)
An inactive device
|
The active phototherapy device will emit light
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in subjective rating of the device across a 3-week intervention
Tidsramme: Change in subjective rating of the device from baseline (pre; Day 0) to after 21 days of wearing it (post)
|
There will be a subjective rating of the phototherapy device using a series of questions assessing device's effect on sleep and next-day function at the end of the trial.
|
Change in subjective rating of the device from baseline (pre; Day 0) to after 21 days of wearing it (post)
|
|
Change in Insomnia Severity Index (ISI) scores across a 3-week intervention
Tidsramme: Change from baseline over the course of the study (after 21 days of wearing the device)
|
The ISI is a 7-item insomnia screening tool that is the gold standard for quantifying severity of clinical insomnia symptoms.
|
Change from baseline over the course of the study (after 21 days of wearing the device)
|
|
Change in objective sleep efficiency across a 3-week intervention
Tidsramme: Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
|
Objective sleep efficiency will be measured with a wearable device (Oura ring) that is worn for the duration of the study and captures sleep and wake data using actigraphy.
|
Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in mean sleep latency assessed using sleep diaries
Tidsramme: Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
|
Sleep latency, or time taken to fall asleep, will be assessed using morning sleep diaries completed by the participant upon awakening.
The mean sleep latency during the baseline period (pre) will be compared to after three weeks of wearing the phototherapy device (post).
|
Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
|
|
Change in Karolinska Sleepiness Scale (KSS) score
Tidsramme: Change from before intervention (pre) to post three weeks of wearing the phototherapy device (Day 21)..
|
The Karolinska Sleepiness Scale (KSS) measures situational sleepiness on a 9-point scale
|
Change from before intervention (pre) to post three weeks of wearing the phototherapy device (Day 21)..
|
|
Circadian Energy Scale (CIRENS) score
Tidsramme: Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
|
CIRENS is a very short and simple chronotype measurement tool based on energy.
The CIRENS consists of two introspective questions about the usual energy level (very low, low, moderate, high, or very high, scored 1 to 5) in the morning and in the evening.
The difference between energy level scores (-4 to 4) felt by respondents in the evening and morning defines the chronotype score and classification.
|
Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
|
|
Positive and Negative Affect Scales (PANAS) Positive Affect
Tidsramme: Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
|
The Positive and Negative Affect Scales are brief screening measures that assess both positive and negative emotional experiences.
This scale will allow for separate assessment of impact on positive mood.
|
Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
|
|
Positive and Negative Affect Scales (PANAS) Negative Affect
Tidsramme: Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
|
The Positive and Negative Affect Scales are brief screening measures that assess both positive and negative emotional experiences.
This scale will allow for separate assessment of impact on negative mood.
|
Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
|
|
Change in Fatigue Severity Scale (FSS) across a three-week intervention
Tidsramme: Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
|
Fatigue Severity Scale (FSS) is a well-validated 9-item clinical measure that assesses overall levels of mental and physical fatigue, with answers ranging from 1- "Strongly Disagree" to 7-"Strongly Agree".
|
Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
|
|
Change in Profile of Mood States (POMS) across a three week intervention
Tidsramme: Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
|
The Profile of Mood States (POMS) is a psychological rating scale used to assess transient, distinct mood states.
The POMS measures six different dimensions of mood swings over a period of time.
These include: Tension or Anxiety, Anger or Hostility, Vigor or Activity, Fatigue or Inertia, Depression or Dejection, Confusion or Bewilderment.
A total score will be evaluated in addition to the individual items.
|
Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
|
|
Change in Wake After Sleep Onset (WASO) assessed using morning sleep diaries over the duration of the study
Tidsramme: Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
|
Wake after sleep onset (WASO), or the number of nocturnal awakenings, will be assessed using morning sleep diaries completed by the participant upon awakening.
The mean WASO during the baseline period (pre) will be compared to after three weeks of wearing the phototherapy device (post).
|
Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
|
|
Change in sleep efficiency assessed using morning sleep diaries over the duration of the study
Tidsramme: Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
|
Sleep efficiency, or the amount of time spent asleep during a sleep opportunity, will be assessed using morning sleep diaries completed by the participant upon awakening.
The mean sleep efficiency during the baseline period (pre) will be compared to after three weeks of wearing the phototherapy device (post).
|
Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
|
|
Change in total sleep time assessed using morning sleep diaries over the duration of the study
Tidsramme: Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
|
Total sleep time will be assessed using morning sleep diaries completed by the participant upon awakening.
The mean total sleep time during the baseline period (pre) will be compared to after three weeks of wearing the phototherapy device (post).
|
Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
|
|
Change in morning refreshed feeling assessed using morning sleep diaries over the duration of the study
Tidsramme: Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
|
Morning refreshed feeling will be assessed using morning sleep diaries completed by the participant upon awakening.
The mean refreshed feeling during the baseline period (pre) will be compared to after three weeks of wearing the phototherapy device (post).
|
Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
2. september 2021
Primær fullføring (Forventet)
30. januar 2022
Studiet fullført (Forventet)
30. januar 2022
Datoer for studieregistrering
Først innsendt
1. november 2021
Først innsendt som oppfylte QC-kriteriene
1. november 2021
Først lagt ut (Faktiske)
11. november 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
11. november 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
1. november 2021
Sist bekreftet
1. november 2021
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 2012256803
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .